A Phase II/III, Multicenter, Observer-blinded, Randomized, Non-inferiority and Safety, study of typhoid conjugate vaccine (EuTCV) compared to Typbar-TCV® in healthy 6 Months-45 years aged participants.
Sign Up to like & getrecommendations! Published in 2023 at "Vaccine"
DOI: 10.2139/ssrn.4229865
Abstract: The typhoid conjugate vaccine (TCV) ensures a long-lasting protective immune response, requires fewer doses and is fit for children under 2 years of age. From Phase I study, EuTCV displayed considerable immunogenicity and reliable safety, thus… read more here.
Keywords: tcv; typbar tcv; phase iii; vaccine ... See more keywords